Home Categories Send inquiry

Olmesartan Medoxomil CAS 144689-63-4 Purity >99.5% (HPLC) API Factory

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Olmesartan Medoxomil (CAS: 144689-63-4) with high quality, commercial production. We can provide Certificate of Analysis (COA), Safety Data Sheet (SDS), worldwide delivery, small and bulk quantities available, strong after-sale service. Welcome to order. Please contact: alvin@ruifuchem.com
Chemical Name Olmesartan Medoxomil
Synonyms 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester; CS-866
CAS Number 144689-63-4
CAT Number RF-PI1730
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C29H30N6O6
Molecular Weight 558.60
Melting Point 180℃ (dec.)
Water Solubility Insoluble in Water; Slightly Soluble in DMSO
Brand Ruifu Chemical
Item Specifications
Appearance White to Almost White Cyrstalline Powder
Identification IR, HPLC, UV: Must Conform to Reference Standard
Purity / Analysis Method >99.5% (HPLC on the Anhydrous and Solvent-Free Basis)
Loss on Drying <0.50%
Residue on Ignition <0.10%
Related Substances
Olmesartan RRT 0.2 <0.50%
Olmesartan Medoxoil Related Compound A. RRT 0.7 <0.20%
Olefinic Impurity RRT 1.6 <0.50%
N-Alkyl Impurity RRT 3.4 <0.10%
Any Other Impurity <0.10%
Total Impurities <0.50%
Heavy Metals (as Pb) <10ppm
pH of Solution (2%, W/V) 4.5 to 6.5
Test Standard Enterprise Standard; USP Standard
Usage API
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture Olmesartan Medoxomil (CS-866) (CAS: 144689-63-4) is a potent and selective angiotensin II type 1 (AT(1)) receptor antagonist with IC50 of 66.2 μM., used in the treatment of high blood pressure. Used as an anti-hypertensive. Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle. By blocking the binding rather than the synthesis of angiotensin II, Olmesartan inhibits the negative regulatory feedback on renin secretion. Olmesartan Medoxomil is a pro-drug that is de-esterified to the active metabolite, olmesartan. Olmesartan Medoxomil was launched in the US as Benicar, an orally administered treatment for hypertension.